In the Margins
Hedge-fund billionaire John Paulson has joined the Valeant Pharmaceuticals International board of directors. Paulson has been one of the largest shareholders in the company for several years, but a series of scandals at Valeant over its accounting practices and drug pricing have battered the company’s stock and caused the value of Paulson’s stake to plunge 81% to $245 million at the end of last year from $1.3 billion in 2015. Read the original story from The Wall Street Journal.
Most Read
Mutual fund chief compliance officers received significant bumps in pay in 2017, according to new data from Management Practice Inc. On average, fund CCO compensation packages ...
When Jamie Baxter retires from the Putnam Funds board at the end of this month, it will mark the culmination of more than 50 years of ...
The board overseeing Diamond Hill Funds has implemented a series of governance policies that set it apart from many other boards in the mutual fund space ...
The rate of increase in pay for independent mutual fund directors was lower again in 2017, continuing a years-long trend that may indicate a normalization of ...